Miacalcin Nasal (Calcitonin (Salmon) Nasal) - Drug Interactions, Contraindications, Overdosage

1. DRUG INTERACTIONS

Formal studies designed to evaluate drug interactions with calcitonin-salmon have not been done. No drug interaction studies have been performed with Miacalcin® (calcitonin-salmon) Nasal Spray ingredients.

Currently, no drug interactions with calcitonin-salmon have been observed. The effects of prior use of diphosphonates in postmenopausal osteoporosis patients have not been assessed; however, in patients with Paget's Disease prior diphosphonate use appears to reduce the anti-resorptive response to Miacalcin® Nasal Spray.

OVERDOSAGE

No instances of overdose with Miacalcin® (calcitonin-salmon) Nasal Spray have been reported and no serious adverse reactions have been associated with high doses. There is no known potential for drug abuse for calcitonin-salmon.

Single doses of Miacalcin® Nasal Spray up to 1600 I.U., doses up to 800 I.U. per day for three days and chronic administration of doses up to 600 I.U. per day have been studied without serious adverse effects. A dose of 1000 I.U. of Miacalcin® injectable solution given subcutaneously may produce nausea and vomiting. A dose of Miacalcin® injectable solution of 32 I.U. per kg per day for one or two days demonstrated no additional adverse effects.

There have been no reports of hypocalcemic tetany. However, the pharmacologic actions of Miacalcin® Nasal Spray suggest that this could occur in overdose. Therefore, provisions for parenteral administration of calcium should be available for the treatment of overdose.

CONTRAINDICATIONS

Clinical allergy to calcitonin-salmon.